Fieldpoint Private Securities’s Novo Nordisk NVO Stock Holding History

Fieldpoint Private Securities’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$847K	Buy	15,194 +5,592	+58%	+$310K	0.25%	99
2022 Q1	$533K	Sell	9,602 -6,290	-40%	-$323K	0.11%	193
2021 Q4	$890K	Buy	15,892 +6,934	+77%	+$376K	0.17%	137
2021 Q3	$430K	Buy	8,958 +1,034	+13%	+$50K	0.1%	221
2021 Q2	$397K	Buy	7,924 +488	+7%	+$18.9K	0.09%	230
2021 Q1	$251K	Buy	7,436 +3,446	+86%	+$123K	0.06%	261
2020 Q4	$139K	Buy	+3,990	New	+$138K	0.03%	342
2019 Q2	–	Sell	-610	Closed	-$16K	–	719
2019 Q1	$16K	Hold	610	–	–	0.01%	342
2018 Q4	$14K	Buy	+610	New	+$13.6K	0.01%	341
2018 Q2	–	Sell	-15,162	Closed	-$373K	–	416
2018 Q1	$373K	Buy	15,162 +1,416	+10%	+$37.2K	0.17%	124
2017 Q4	$369K	Sell	13,746 -1,684	-11%	-$42.8K	0.19%	120
2017 Q3	$371K	Buy	15,430 +11,430	+286%	+$258K	0.16%	136
2017 Q2	$86K	Buy	4,000 +3,530	+751%	+$71.2K	0.06%	96
2017 Q1	$8K	Buy	+470	New	+$8.18K	0.01%	316

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fieldpoint Private Securities's NVO Position: Q2 2022 in Review

Fieldpoint Private Securities increased its Novo Nordisk (NVO) stake by 58% in Q2 2022, buying an estimated $310K and bringing the position to 15,194 shares worth $847K. The position accounts for 0.25% of the portfolio, ranked #99.

Fieldpoint Private Securities first reported a position in NVO in Q1 2017 and has held it in 14 quarters since. The position peaked at $890K in Q4 2021. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

Fieldpoint Private Securities held 15,194 shares of Novo Nordisk worth $847K as of Q2 2022.
Fieldpoint Private Securities bought 5,592 Novo Nordisk shares in Q2 2022, an estimated $310K.
Novo Nordisk made up 0.25% of Fieldpoint Private Securities's portfolio in Q2 2022, its #99 holding.
Fieldpoint Private Securities first reported a position in Novo Nordisk in Q1 2017 and has held it in 14 quarters since.
Fieldpoint Private Securities's Novo Nordisk position peaked at $890K in Q4 2021.
932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.